Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Vyome Holdings Inc HIND

Healthcare Medical Devices
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2... see more

Current News (NDAQ:HIND)

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

Business Wire 22 hours ago

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

Business Wire April 22, 2026

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Business Wire April 6, 2026

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Business Wire March 26, 2026

Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

Business Wire February 24, 2026

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Business Wire February 18, 2026

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Business Wire February 11, 2026

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Business Wire February 2, 2026

Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Business Wire January 27, 2026
View More News ››

Opinion & Analysis (NDAQ:HIND)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:HIND)

Buy buddy buy.

Otherwise it will be FOMO time for you fellas out there today
coolfooldumbguy - September 17, 2025
View more Bullboard ››

Sekur Private Data Ltd.

Sekur Private Data Ltd.

Sekur Private Data Ltd. operates as a cybersecurity and internet privacy provider of Swiss hosted solutions for secure ...
View More »

Podcasts